Adjuvant bisphosphonates or RANK-ligand inhibitors for patients with breast cancer and bone metastases: A systematic review and network meta-analysis

Anastasilakis, 2009, Efficacy and safety of denosumab in postmenopausal women with osteopenia or osteoporosis: a systematic review and a meta-analysis, Horm. Metab. Res., 41, 721, 10.1055/s-0029-1224109 Barrett-Lee, 2014, Oral ibandronic acid versus intravenous zoledronic acid in treatment of bone metastases from breast cancer: a randomised, open label, non-inferiority phase 3 trial, Lancet Oncol., 114, 10.1016/S1470-2045(13)70539-4 Bartsch, 2010, Breast Cancer: rank ligand inhibition, Breast Care Basel (Basel), 5, 320, 10.1159/000321122 Berenson, 2001, Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases, Cancer, 91, 1191, 10.1002/1097-0142(20010401)91:7<1191::AID-CNCR1119>3.0.CO;2-0 Body, 2003, Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases, Ann. Oncol., 14, 1399, 10.1093/annonc/mdg367 Body, 2004, Oral ibandronate improves bone pain and preserves quality of life in patients with skeletal metastases due to breast cancer, Pain, 111, 306, 10.1016/j.pain.2004.07.011 Cipriani, 2013, Conceptual and technical challenges in network meta-analysis, Ann. Intern. Med., 159, 130, 10.7326/0003-4819-159-2-201307160-00008 Coleman, 2008, Risks and benefits of bisphosphonates, Br. J. Cancer, 98, 1736, 10.1038/sj.bjc.6604382 Conte, 1996, Delay in progression of bone metastases in breast cancer patients treated with intravenous pamidronate: results from a multinational randomized controlled trial. The Aredia Multinational Cooperative Group, J. Clin. Oncol., 14, 2552, 10.1200/JCO.1996.14.9.2552 Coxon, 2000, Protein geranylgeranylation is required for osteoclast formation, function, and survival: inhibition by bisphosphonates and GGTI-298, J. Bone Miner. Res., 15, 1467, 10.1359/jbmr.2000.15.8.1467 Egger, 1997, Bias in meta-analysis detected by a simple, graphical test, Bmj, 315, 629, 10.1136/bmj.315.7109.629 Elomaa, 1983, Long-term controlled trial with diphosphonate in patients with osteolytic bone metastases, Lancet, 1, 146, 10.1016/S0140-6736(83)92755-1 Elomaa, 1988, Clodronate for osteolytic metastases due to breast cancer, Biomed. Pharmacother., 42, 111 Fizazi, 2009, Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates, J. Clin. Oncol., 27, 1564, 10.1200/JCO.2008.19.2146 Greco, 2013, Meta-analysis: pitfalls and hints, Heart Lung Vessel., 5, 219 Greco, 2016, A Bayesian network meta-analysis for binary outcome: how to do it, Stat. Methods Med. Res., 25, 1757, 10.1177/0962280213500185 Harrington, 2014, Breast Cancer edge task force outcomes: clinical measures of pain, Rehabil. Oncol., 32, 13, 10.1097/01893697-201432010-00004 Healey, 2000, Complications of bone metastases: surgical management, Cancer, 88, 2940, 10.1002/1097-0142(20000615)88:12+<2940::AID-CNCR10>3.0.CO;2-W Hellstein, 2011, Managing the care of patients receiving antiresorptive therapy for prevention and treatment of osteoporosis: executive summary of recommendations from the American Dental Association Council on Scientific Affairs, J. Am. Dent. Assoc., 142, 1243, 10.14219/jada.archive.2011.0108 Heras, 2009, Efficacy of ibandronate for the treatment of skeletal events in patients with metastatic breast cancer, Eur. J. Cancer Care (Engl), 18, 653, 10.1111/j.1365-2354.2008.00980.x Higgins, 2003, Measuring inconsistency in meta-analyses, Bmj, 327, 557, 10.1136/bmj.327.7414.557 Higgins, 2011, The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials, Bmj, 343, d5928, 10.1136/bmj.d5928 Higgins, 2012, Consistency and inconsistency in network meta-analysis: concepts and models for multi-arm studies, Res. Synth. Methods, 3, 98, 10.1002/jrsm.1044 Hortobagyi, 1996, Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group, N Engl. J. Med., 335, 1785, 10.1056/NEJM199612123352401 Howlader N, Noone AM, Krapcho M et al. SEER Cancer Statistics Review, 1975-2010. In National Cancer Institute. Bethesda, MD. Hultborn, 1999, Efficacy of pamidronate in breast cancer with bone metastases: a randomized, double-blind placebo-controlled multicenter study, Anticancer Res., 19, 3383 Kohno, 2005, Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial, J. Clin. Oncol., 23, 3314, 10.1200/JCO.2005.05.116 Kristensen, 1999, Oral clodronate in breast cancer patients with bone metastases: a randomized study, J. Intern. Med., 246, 67, 10.1046/j.1365-2796.1999.00507.x Lipton, 2008, Extended efficacy and safety of denosumab in breast cancer patients with bone metastases not receiving prior bisphosphonate therapy, Clin. Cancer Res., 14, 6690, 10.1158/1078-0432.CCR-07-5234 Luedders, 2015, Lack of difference in acute nephrotoxicity of intravenous bisphosphonates zoledronic acid and ibandronate in women with breast cancer and bone metastases, Anticancer Res., 35, 1797 Martin, 2017, Spinal multiparametric MRI and DEXA changes over time in men with prostate cancer treated with androgen deprivation therapy: a potential imaging biomarker of treatment toxicity, Eur. Radiol., 27, 995, 10.1007/s00330-016-4434-z Martoni, 1991, Controlled clinical study on the use of dichloromethylene diphosphonate in patients with breast carcinoma metastasizing to the skeleton, Oncology, 48, 97, 10.1159/000226904 Moher, 2009, Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement, J. Clin. Epidemiol., 62, 1006, 10.1016/j.jclinepi.2009.06.005 Monnot, 2017, Rationale for immunological approaches to breast cancer therapy, Breast, 37, 187, 10.1016/j.breast.2017.06.009 O’Shaughnessy, 2005, Extending survival with chemotherapy in metastatic breast cancer, Oncologist, 10, 20, 10.1634/theoncologist.10-90003-20 Paterson, 1993, Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer, J. Clin. Oncol., 11, 59, 10.1200/JCO.1993.11.1.59 Qi, 2013, Risk of osteonecrosis of the jaw in cancer patients receiving denosumab: a meta-analysis of seven randomized controlled trials, Int. J. Clin. Oncol., 19, 403, 10.1007/s10147-013-0561-6 R-Core-Team, 2018 Ripamonti, 2012, Management of cancer pain: ESMO clinical practice guidelines, Ann. Oncol., 23 Rogers, 1999, Molecular mechanisms of action of bisphosphonates, Bone, 24, 73, 10.1016/S8756-3282(99)00070-8 Roodman, 2004, Mechanisms of bone metastasis, N. Engl. J. Med., 350, 1655, 10.1056/NEJMra030831 Rosen, 2001, Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial, Cancer J., 7, 377 Ross, 2003, Systematic review of role of bisphosphonates on skeletal morbidity in metastatic cancer, Bmj, 327, 469, 10.1136/bmj.327.7413.469 Rücker, 2012, Network meta-analysis, electrical networks and graph theory, Res. Synth. Methods, 3, 312, 10.1002/jrsm.1058 Rücker, 2012, Network meta‐analysis, electrical networks and graph theory, Res. Synth. Methods, 3, 312, 10.1002/jrsm.1058 Rücker, 2015, Ranking treatments in frequentist network meta-analysis works without resampling methods, BMC Med. Res. Methodol., 15, 1, 10.1186/s12874-015-0060-8 Rücker, 2018 Russell, 1999, The pharmacology of bisphosphonates and new insights into their mechanisms of action, J. Bone Miner. Res., 14, 53, 10.1002/jbmr.5650140212 Schwartz, 2017, Timing of metastasis in breast Cancer, N. Engl. J. Med., 376, 2486, 10.1056/NEJMcibr1701388 Schwarzer, 2007, 7, 40 Schwarzer, 2015, Chapter 8: network meta-analysis Shiozawa, 2015, Bone marrow as a metastatic niche for disseminated tumor cells from solid tumors, Bonekey Rep., 4, 1, 10.1038/bonekey.2015.57 So, 2012, Management of skeletal-related events in patients with advanced prostate cancer and bone metastases: incorporating new agents into clinical practice, Can. Urol. Assoc. J., 6, 465, 10.5489/cuaj.117 Song, 2009, Methodological problems in the use of indirect comparisons for evaluating healthcare interventions: survey of published systematic reviews, Bmj, 338, b1147, 10.1136/bmj.b1147 Stopeck, 2010, Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study, J. Clin. Oncol., 28, 5132, 10.1200/JCO.2010.29.7101 Theriault, 1999, Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial. Protocol 18 Aredia Breast Cancer Study Group, J. Clin. Oncol., 17, 846, 10.1200/JCO.1999.17.3.846 Tierney, 2007, Practical methods for incorporating summary time-to-event data into meta-analysis, Trials, 8, 16, 10.1186/1745-6215-8-16 Tripathy, 2004, Oral ibandronate for the treatment of metastatic bone disease in breast cancer: efficacy and safety results from a randomized, double-blind, placebo-controlled trial, Ann. Oncol., 15, 743, 10.1093/annonc/mdh173 van Holten-Verzantvoort, 1991, The effect of supportive pamidronate treatment on aspects of quality of life of patients with advanced breast cancer, Eur. J. Cancer, 27, 544, 10.1016/0277-5379(91)90212-V Van Poznak, 2011, American Society of Clinical Oncology executive summary of the clinical practice guideline update on the role of bone-modifying agents in metastatic breast cancer, J. Clin. Oncol., 29, 1221, 10.1200/JCO.2010.32.5209 Velentgas, 2013, Outcome definition and measurement, 71 Wang, 2015, Systematic literature review and network meta-analysis comparing bone-targeted agents for the prevention of skeletal-related events in cancer patients with bone metastasis, Oncologist, 20, 440, 10.1634/theoncologist.2014-0328